Erratum: Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects (Molecular Therapy: Oncology (2026) 34(1), (S2950329925001924), (10.1016/j.omton.2025.201123))

Manikandan Santhanam; Venkatadri Babu; Anna Shteinfer-Kuzmine; Swaroop Kumar Pandey; Larisa Gheber; Gilead Raday; Varda Shoshan-Barmatz

doi:10.1016/j.omton.2026.201142

Erratum: Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects (Molecular Therapy: Oncology (2026) 34(1), (S2950329925001924), (10.1016/j.omton.2025.201123))

Manikandan Santhanam
, Venkatadri Babu
, Anna Shteinfer-Kuzmine
, Swaroop Kumar Pandey
, Larisa Gheber
, Gilead Raday
, Varda Shoshan-Barmatz

Research output: Contribution to journal › Comment/debate

Abstract

(Molecular Therapy: Oncology 34, 1−25; March 2026) In the originally published version of this article, KMH2-LC cells were incorrectly described as human anaplastic thyroid carcinoma but should be KMH2 (human Hodgkin lymphoma). The authors apologize for this error.

Original language	English
Article number	201142
Journal	Molecular Therapy Oncology
Volume	34
Issue number	1
DOIs	https://doi.org/10.1016/j.omton.2026.201142
State	Published - 19 Mar 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Molecular Medicine
Oncology
Cancer Research
Pharmacology (medical)

Access to Document

10.1016/j.omton.2026.201142

Fingerprint

Dive into the research topics of 'Erratum: Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects (Molecular Therapy: Oncology (2026) 34(1), (S2950329925001924), (10.1016/j.omton.2025.201123))'. Together they form a unique fingerprint.

Cite this

Santhanam, M., Babu, V., Shteinfer-Kuzmine, A., Pandey, S. K., Gheber, L., Raday, G., & Shoshan-Barmatz, V. (2026). Erratum: Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects (Molecular Therapy: Oncology (2026) 34(1), (S2950329925001924), (10.1016/j.omton.2025.201123)). Molecular Therapy Oncology, 34(1), Article 201142. https://doi.org/10.1016/j.omton.2026.201142

@article{211073dfceab40ce923e055a05c9b55e,

title = "Erratum: Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects (Molecular Therapy: Oncology (2026) 34(1), (S2950329925001924), (10.1016/j.omton.2025.201123))",

abstract = "(Molecular Therapy: Oncology 34, 1−25; March 2026) In the originally published version of this article, KMH2-LC cells were incorrectly described as human anaplastic thyroid carcinoma but should be KMH2 (human Hodgkin lymphoma). The authors apologize for this error.",

author = "Manikandan Santhanam and Venkatadri Babu and Anna Shteinfer-Kuzmine and Pandey, \{Swaroop Kumar\} and Larisa Gheber and Gilead Raday and Varda Shoshan-Barmatz",

note = "Publisher Copyright: {\textcopyright} 2026 The Author(s)",

year = "2026",

month = mar,

day = "19",

doi = "10.1016/j.omton.2026.201142",

language = "English",

volume = "34",

journal = "Molecular Therapy Oncology",

issn = "2372-7705",

publisher = "Cell Press",

number = "1",

}

Santhanam, M, Babu, V, Shteinfer-Kuzmine, A, Pandey, SK, Gheber, L, Raday, G & Shoshan-Barmatz, V 2026, 'Erratum: Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects (Molecular Therapy: Oncology (2026) 34(1), (S2950329925001924), (10.1016/j.omton.2025.201123))', Molecular Therapy Oncology, vol. 34, no. 1, 201142. https://doi.org/10.1016/j.omton.2026.201142

Erratum: Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects (Molecular Therapy: Oncology (2026) 34(1), (S2950329925001924), (10.1016/j.omton.2025.201123)). / Santhanam, Manikandan; Babu, Venkatadri; Shteinfer-Kuzmine, Anna et al.
In: Molecular Therapy Oncology, Vol. 34, No. 1, 201142, 19.03.2026.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum

T2 - Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects (Molecular Therapy: Oncology (2026) 34(1), (S2950329925001924), (10.1016/j.omton.2025.201123))

AU - Santhanam, Manikandan

AU - Babu, Venkatadri

AU - Shteinfer-Kuzmine, Anna

AU - Pandey, Swaroop Kumar

AU - Gheber, Larisa

AU - Raday, Gilead

AU - Shoshan-Barmatz, Varda

PY - 2026/3/19

Y1 - 2026/3/19

N2 - (Molecular Therapy: Oncology 34, 1−25; March 2026) In the originally published version of this article, KMH2-LC cells were incorrectly described as human anaplastic thyroid carcinoma but should be KMH2 (human Hodgkin lymphoma). The authors apologize for this error.

AB - (Molecular Therapy: Oncology 34, 1−25; March 2026) In the originally published version of this article, KMH2-LC cells were incorrectly described as human anaplastic thyroid carcinoma but should be KMH2 (human Hodgkin lymphoma). The authors apologize for this error.

UR - https://www.scopus.com/pages/publications/105028949721

U2 - 10.1016/j.omton.2026.201142

DO - 10.1016/j.omton.2026.201142

M3 - Comment/debate

C2 - 41659921

AN - SCOPUS:105028949721

SN - 2372-7705

VL - 34

JO - Molecular Therapy Oncology

JF - Molecular Therapy Oncology

IS - 1

M1 - 201142

ER -

Santhanam M, Babu V, Shteinfer-Kuzmine A, Pandey SK, Gheber L, Raday G et al. Erratum: Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects (Molecular Therapy: Oncology (2026) 34(1), (S2950329925001924), (10.1016/j.omton.2025.201123)). Molecular Therapy Oncology. 2026 Mar 19;34(1):201142. doi: 10.1016/j.omton.2026.201142

Erratum: Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects (Molecular Therapy: Oncology (2026) 34(1), (S2950329925001924), (10.1016/j.omton.2025.201123))

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this